Understanding the Structure of a PBRER

A Periodic Benefit-Risk Evaluation Report (PBRER) is not a collection of independent template sections. Its structure is designed to support a cumulative scientific argument: establish the regulatory and exposure context, present the important new and cumulative evidence, evaluate signals and risks, reassess benefits, and then integrate those findings into an overall benefit-risk conclusion.

Purpose and Regulatory Framework

The PBRER format is defined by ICH E2C(R2), adopted at Step 4 in November 2012. In the European Union, the corresponding periodic report is the PSUR, whose format and content are legally required under Commission Implementing Regulation (EU) No 520/2012 and further described in GVP Module VII — Periodic safety update report (Rev. 1).

ICH E2C(R2) changed periodic reporting from a primarily interval-based safety summary toward a cumulative benefit-risk evaluation. The ICH implementation Q&A emphasises that the broader scope requires information to be integrated across the report rather than handled as isolated sections.

As of September 2026, EMA continues to publish GVP Module VII Rev. 1 while noting that GVP modules will be updated following amendments to Commission Implementing Regulation (EU) No 520/2012. Current EU procedural advice should therefore be checked for submission-specific requirements.

The PBRER as a Scientific Argument

The structure can be understood as four connected phases:

1. context — what product, authorisation status, reference information and exposure frame the evaluation;
2. evidence — what new and cumulative safety and benefit information is available;
3. evaluation — what that evidence means for signals, risks and benefits; and
4. integration — whether the overall benefit-risk balance has changed and what action follows.

This progression matters because conclusions in the final sections depend on assumptions and evidence established earlier.

Why Descriptive Sections Matter

Authors sometimes treat descriptive sections as administrative content to be completed independently of the medical evaluation. That is a mistake.

For example:

• worldwide marketing status helps define regulatory context;
• actions taken for safety reasons show how other authorities or the MAH have already responded;
• changes to reference safety information define what was considered known during the interval;
• exposure data provide the population context needed to interpret safety observations.

These sections do not usually contain the report's deepest scientific reasoning, but they create the frame within which later evidence is interpreted.

Section 1: Introduction

The introduction identifies the product and report context. It should orient the assessor without duplicating the entire report.

Important elements include:

• reporting interval;
• international birth date where applicable;
• medicinal product and indication context;
• brief description of the report's scope; and
• any important information needed to understand unusual reporting circumstances.

The introduction should not contain conclusions that properly belong in later benefit-risk sections.

Section 2: Worldwide Marketing Authorisation Status

This section establishes where the product is authorised and any important differences relevant to the report.

Its value becomes clearer later when interpreting:

• geographic differences in exposure;
• differences in indications;
• regulatory actions in particular regions; and
• changes in the authorised population.

Section 3: Actions Taken in the Reporting Interval for Safety Reasons

This section records significant safety-related action during the interval. It is not simply a chronology. It helps the assessor understand whether new evidence has already resulted in restriction, communication, study activity or other risk-management action.

Later sections should explain the evidence and benefit-risk reasoning behind those actions where relevant.

Section 4: Changes to Reference Safety Information

The reference safety information defines the safety context against which new information is interpreted. Changes during the interval can alter whether an event is considered expected or newly characterised and may reflect important signal conclusions.

The author should ensure that changes described here are consistent with the later signal and risk discussions.

Section 5: Estimated Exposure and Use Patterns

Exposure converts a list of events into a clinically interpretable context. Depending on the product and available data, the report may discuss cumulative subject exposure in clinical trials and cumulative and interval patient exposure from marketing experience.

Exposure estimates often contain uncertainty. Assumptions, data sources and important limitations should be transparent because later interpretations of frequency, public-health impact and benefit-risk depend on them.

Sections 6 to 11: Building the Safety Evidence Base

The middle of the PBRER progressively assembles the safety information needed for later interpretation. These sections should not all be written with the same level of analysis. Some are primarily descriptive repositories of evidence; others begin the transition toward synthesis.

Section 6: Data in Summary Tabulations

Summary tabulations provide structured cumulative and interval safety data. Their purpose is to make the safety experience visible in a standardised form and support subsequent analysis.

The tables should be internally consistent with the case and exposure data used elsewhere in the report. They should not be treated as a substitute for medical interpretation.

Section 7: Summaries of Significant Findings From Clinical Trials

Clinical-trial evidence is particularly valuable because it can provide structured exposure, comparator information and prospectively collected events. The section should focus on findings that materially inform the safety profile rather than repeat every result from every study.

Where important trial results affect a signal or identified risk, those connections should become explicit in later evaluation sections.

Section 8: Findings From Non-Interventional Studies

Observational and pharmacoepidemiological evidence can help characterise incidence, comparative risk, special populations and real-world use. Study design and limitations matter because confounding, selection and outcome misclassification can substantially affect interpretation.

This section should therefore present enough methodological context for the reader to understand how much weight the study should carry later.

Section 9: Information From Other Clinical Trials and Sources

Relevant information may arise from compassionate use, registries, investigator-initiated research, combination studies, partner data or other sources not fully captured elsewhere.

The governing principle is relevance to the benefit-risk evaluation. The section should not become an inventory of every available dataset.

Section 10: Non-Clinical Data

New toxicology, pharmacology or mechanistic findings may influence interpretation of clinical safety concerns. Non-clinical evidence is particularly important where it provides biological plausibility or identifies a risk not yet well characterised in humans.

The author should avoid overstating mechanistic findings as proof of clinical causality.

Section 11: Literature

The literature section captures important published evidence relevant to safety, efficacy/effectiveness and benefit-risk. It should integrate the output of the literature-monitoring process without duplicating individual publication summaries unnecessarily.

The most important publications should be connected to the relevant signal, risk or benefit discussion later in the report.

Sections 12 and 13: Other Reports and Lack of Efficacy

Section 12: Other Periodic Reports

Where multiple periodic reports exist for the same active substance or related formulations, the PBRER may need to explain important information arising from those reports and its relevance to the current evaluation.

The section is primarily contextual. Its purpose is to avoid fragmented assessment across overlapping reporting systems.

Section 13: Lack of Efficacy in Controlled Clinical Trials

Lack of efficacy can become a safety or benefit-risk issue when failure of treatment has serious consequences. The relevance depends strongly on therapeutic context.

For a medicine used to prevent a life-threatening outcome, evidence of reduced efficacy may materially alter benefit-risk even without a new adverse reaction. This illustrates why the PBRER is broader than a conventional safety report.

Section 14: Late-Breaking Information

Late-breaking information captures important data received after the formal data lock point but before report finalisation when the information is sufficiently significant that omission would make the report misleading or incomplete.

This section should not be used to circumvent the data lock point or introduce routine new data indiscriminately. The author should explain why the information is important and how it affects the report's conclusions.

Section 15: Overview of Signals

This section provides a structured overview of signals that were new, ongoing or closed during the reporting interval.

It functions as a bridge between the descriptive evidence sections and the detailed scientific evaluation that follows. The overview should be consistent with the organisation's signal-management records and should make clear which issues require detailed discussion.

The section should not imply that every statistical alert or observation became a validated signal.

Section 16: Signal and Risk Evaluation

This is one of the scientific cores of the PBRER. It evaluates new and ongoing signals and re-examines important identified and potential risks in light of cumulative evidence.

A strong evaluation should explain:

• the safety question being assessed;
• evidence supporting the association;
• evidence arguing against it;
• limitations and uncertainty;
• whether the risk is new, changed or better characterised;
• whether additional data are needed; and
• whether product information, RMP content, pharmacovigilance or risk minimisation should change.

The section should be internally consistent with the detailed signal-assessment records maintained outside the PBRER.

Section 16.1: Summary of Safety Concerns

The report should provide a clear current view of important safety concerns relevant to ongoing benefit-risk management. This should align with the RMP where applicable, while recognising that the PBRER and RMP serve different regulatory functions.

The PBRER evaluates cumulative evidence over time; the RMP defines the current risk-management strategy. The two documents should inform one another without being mechanically identical.

Sections 16.2–16.4: Signal Evaluation and Characterisation of Risks

The structure of Section 16 moves from specific signal evaluation toward broader characterisation of established and potential risks. The author should avoid treating each subsection as isolated.

For example, a newly validated hepatic signal may be evaluated in detail, then—if the evidence supports the association—its incidence, severity, reversibility, susceptible populations and preventability may be characterised as part of the cumulative risk profile.

This progression demonstrates how a hypothesis can evolve into a more mature understanding of risk.

Section 17: Benefit Evaluation

The benefit section reassesses important evidence about efficacy or effectiveness in the context of current use. The PBRER is not intended to reproduce the original efficacy dossier. The purpose is to determine whether new information changes the understanding of benefit that is relevant to the current benefit-risk balance.

Relevant developments may include:

• new comparative efficacy data;
• effectiveness in routine clinical practice;
• evidence in important subpopulations;
• durability of benefit;
• changes in treatment alternatives; or
• clinically important lack-of-efficacy information.

The depth of discussion should reflect whether the benefit profile has changed materially.

Section 18: Integrated Benefit-Risk Analysis for Approved Indications

Section 18 is the point at which the report's preceding evidence is integrated. It should not be a second summary of Sections 16 and 17.

A high-quality benefit-risk analysis explains:

1. the important benefits relevant to the authorised indication;
2. the important risks and uncertainties;
3. how new evidence changes—or does not change—those benefits and risks;
4. which patient groups or clinical contexts alter the balance;
5. whether risk minimisation changes the practical impact of a risk; and
6. why the overall balance remains favourable or requires action.

The conclusion should follow logically from the evidence already presented. New major evidence should not appear for the first time in this section.

Section 19: Conclusions and Actions

The final section converts the integrated evaluation into a clear regulatory and pharmacovigilance conclusion.

Possible outcomes include:

• no change to the overall benefit-risk conclusion;
• continued monitoring of a defined issue;
• further signal assessment;
• RMP revision;
• product-information change;
• additional pharmacovigilance;
• new or modified risk minimisation; or
• other regulatory action.

The section should distinguish between an action that the MAH proposes, an action already agreed with a competent authority and an internal activity that is not itself a regulatory commitment.

How the Sections Should Connect

The report is strongest when the same scientific issue can be followed through several sections without inconsistency.

Consider an illustrative signal of acute kidney injury:

• Section 5 provides relevant exposure context.
• Sections 6–11 contain case, trial, study and literature evidence.
• Section 15 identifies the signal and its interval status.
• Section 16 evaluates the association and characterises the risk.
• Section 17 determines whether benefit information has changed.
• Section 18 evaluates the overall benefit-risk implications.
• Section 19 states the resulting action.

The reader should not encounter a different conclusion in each section. Each section performs a different analytical function within one argument.

Common Structural Failure Modes

The following are illustrative writing and review failure modes, not regulatory inspection findings.

Practical Cross-Section Review

A useful final review asks:

1. Does the introduction define the reporting context clearly?
2. Are regulatory actions and reference-safety changes reflected later in the scientific evaluation?
3. Are exposure estimates consistent wherever they are used?
4. Do summary tabulations reconcile with the underlying safety datasets?
5. Are important study and literature findings carried into relevant signal or risk evaluations?
6. Does the signal overview reconcile with the signal-management system?
7. Are risk conclusions consistent with the RMP where relevant?
8. Does the benefit section focus on information relevant to the current evaluation?
9. Does the integrated benefit-risk analysis weigh benefits and risks rather than merely summarise them?
10. Do conclusions and proposed actions follow directly from the integrated evaluation?
11. Are uncertainties and limitations stated consistently?
12. Can an assessor follow one important safety issue through the entire report without encountering contradiction?

Relationship With Other QPPV.com PBRER Articles

This article explains why the PBRER is structured as it is and how its sections connect.

For the wider regulatory and procedural framework, including EU PSUR requirements, EURD considerations and PSUSA, see [[pbrer-guide]].

For detailed section-by-section authoring practice, see [[how-to-write-a-pbrer]]. These articles are complementary rather than alternative versions of the same guide.

Key Takeaways

The PBRER is a cumulative benefit-risk evaluation, not a bundle of independent reporting sections.

Its structure deliberately progresses from regulatory and exposure context through evidence collection, signal and risk evaluation, benefit evaluation and integrated benefit-risk judgement.

Descriptive sections matter because they establish the context used by later medical interpretation. Scientific sections should build on that evidence rather than repeat it.

The integrated benefit-risk section should contain synthesis, not new evidence, and the final conclusions should translate that synthesis into proportionate actions.

A well-written PBRER allows the assessor to follow an important issue across the report as one coherent scientific argument.

References

1. International Council for Harmonisation. ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). Step 4, 15 November 2012; corrigendum 17 December 2012. https://database.ich.org/sites/default/files/E2C_R2_Guideline.pdf
2. International Council for Harmonisation. ICH E2C(R2) Questions and Answers. Last update 31 March 2014. https://database.ich.org/sites/default/files/E2CR2_Q%26As_Q%26As.pdf
3. European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Module VII — Periodic safety update report (Rev. 1). EMA/816292/2011 Rev. 1. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf
4. European Medicines Agency. Periodic safety update reports (PSURs). Current procedural guidance and questions and answers.
5. European Medicines Agency. European Medicines Agency post-authorisation procedural advice for users of the centralised procedure. EMEA-H-19984/03 Rev. 118, updated 13 July 2026.
6. European Union. Commission Implementing Regulation (EU) No 520/2012, as amended.
7. European Union. Directive 2001/83/EC, as amended.
8. European Union. Regulation (EC) No 726/2004, as amended.

Regulatory Note

This article explains the scientific architecture of the ICH E2C(R2) PBRER and its implementation in the EU PSUR framework. It does not replace the applicable PSUR submission procedure, EURD-list requirements or current EMA procedural advice. As of 8 September 2026, GVP Module VII Rev. 1 remains the published EMA module, while EMA has stated that GVP modules will be revised following amendments to Commission Implementing Regulation (EU) No 520/2012.